Mid Atlantic Retina | Cherry Hill, NJ

Research site

(Unclaimed)

Location

8 Ronaldo Terrace, Cherry Hill, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Eplerenone

Elamipretide

ANX007

EYP-1901

Pegcetacoplan

Vamikibart

Parent organization

This site is a part of Mid Atlantic Retina

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 12 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling

Neovascular Age-related Macular Degeneration

Device: SUSVIMO PDS Implant

Drug: LUCENTIS (ranibizumab injection)

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling

Geographic Atrophy

Drug: ANX007

Other: Sham Administration

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Enrolling

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Ranibizumab refill exchange

Locations recently updated

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling

Geographic Atrophy

Biological: OpRegen

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling

Age Related Macular Degeneration (ARMD)

Drug: Elamipretide

Drug: Placebo

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (ArMaDa)

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD)....

Active, not recruiting

Geographic Atrophy

Genetic: OCU410